| A Dose Escalation Study of Hydroxyurea in Combination With SCH900776 in Advanced Malignant Solid Tumors (NCT01521299) | Dartmouth-Hitchcock Medical Center | 2012-03-01 |
| A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or Lymphomas (NCT01512758) | Millennium Pharmaceuticals, Inc. | 2012-02-06 |
| Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors (NCT01482156) | Novartis Pharmaceuticals | 2012-01-01 |
| Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment (NCT01520389) | Merrimack Pharmaceuticals | 2012-01-01 |
| A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2) (NCT01433991) | Eisai Inc. | 2011-10-13 |
| Study of ABT-700 in Subjects With Advanced Solid Tumors (NCT01472016) | AbbVie (prior sponsor, Abbott) | 2011-10-06 |
| An Extension Study of ABT-806 in Subjects With Advanced Solid Tumors (NCT01406119) | AbbVie (prior sponsor, Abbott) | 2011-10-01 |
| An Evaluation of the Biodistribution and Imaging Characteristics of ABT-806i (111In-ABT-806) in Subjects With Advanced Solid Tumor Types (NCT01472003) | AbbVie (prior sponsor, Abbott) | 2011-10-01 |
| A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function (NCT01331941) | Amgen | 2011-09-19 |
| Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients (NCT01363232) | Array Biopharma, now a wholly owned subsidiary of Pfizer | 2011-08-01 |
| A Pharmacokinetic Study to Access How the Body Absorbs and Removes Linifanib in Male Patients With Advanced Solid Tumors. (NCT01286974) | Abbott | 2011-08-01 |
| Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies. (NCT01636908) | Amsterdam UMC, location VUmc | 2011-08-01 |
| MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations (NCT01352273) | Array Biopharma, now a wholly owned subsidiary of Pfizer | 2011-06-01 |
| Effect on QTc, Pharmacokinetics, Safety, and Preliminary Efficacy of Single-agent Palifosfamide-tris in Subjects With Advanced Solid Tumors (NCT01340547) | Alaunos Therapeutics | 2011-06-01 |
| An Extension Study of Linifanib (ABT-869) in Subjects With Advanced or Metastatic Solid Tumors (NCT01413893) | AbbVie | 2011-06-01 |
| To Compare Relative Bioavailability of Two Clinical Formulations of Linifanib. (NCT01381341) | Abbott | 2011-05-01 |
| Effect of Rifampin on the Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors (NCT01401933) | Abbott | 2011-05-01 |
| A Clinical Pharmacodynamic and Pharmacogenetic Study of OPB-51602 in Patients With Advanced Solid Tumours (NCT01867073) | National University Hospital, Singapore | 2011-05-01 |
| QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas (NCT01231347) | NantCell, Inc. | 2011-04-07 |
| Study of Tesetaxel in Japanese Patients With Solid Tumors (NCT01337310) | Genta Incorporated | 2011-04-01 |
| Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) (NCT01327612) | Amgen | 2011-03-03 |
| MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies (NCT01235897) | University of California, San Francisco | 2011-03-01 |
| A Phase 1 Trial of ABI-011 in Patients With Advanced Solid Tumors or Lymphomas (NCT01163071) | Celgene | 2011-03-01 |
| Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors (NCT01302405) | Prism Pharma Co., Ltd. | 2011-02-01 |
| Study of Intravenous TCD-717 in Patients With Advanced Solid Tumors (NCT01215864) | Traslational Cancer Drugs Pharma, SL | 2011-01-01 |
| A Dose-escalation Study of Ombrabulin in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumors (NCT01293630) | Sanofi | 2011-01-01 |
| A Study of AMG 337 in Subjects With Advanced Solid Tumors (NCT01253707) | Amgen | 2010-12-08 |
| A Study of ABT-806 in Subjects With Advanced Solid Tumor Types (NCT01255657) | AbbVie (prior sponsor, Abbott) | 2010-11-01 |
| A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors (NCT01248949) | MedImmune LLC | 2010-10-01 |
| A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors (NCT01106508) | Novartis Pharmaceuticals | 2010-10-01 |
| A Cardiac Safety Study of Tivozanib to Evaluate the Electrocardiogram and Pharmacokinetic-Electrocardiogram Dynamics in Subjects With Advanced Solid Tumors (NCT01210846) | AVEO Pharmaceuticals, Inc. | 2010-10-01 |
| An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols (NCT01178411) | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 2010-08-31 |
| A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen (NCT01094288) | Millennium Pharmaceuticals, Inc. | 2010-08-17 |
| Study of NK012 and 5-FU/LV in Solid Tumors Followed by Dose Expansion in Colorectal Cancer (NCT01238939) | Nippon Kayaku Co., Ltd. | 2010-08-01 |
| Targeted Therapy Selection Based on Tumor Tissue Kinase Activity Profiles for Patients With Advanced Solid Malignancies, an Exploratory Study (NCT01190241) | Amsterdam UMC, location VUmc | 2010-08-01 |
| Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer (NCT01238952) | Nippon Kayaku Co., Ltd. | 2010-07-01 |
| An Open-label Study Investigating the Disposition and QT/QTc Interval Effects of 400 mg [14C]-Iniparib(3.7 MBq, 100 µCi) (NCT01161836) | Sanofi | 2010-07-01 |
| A Study of Temsirolimus Plus Capecitabine in Patients With Advanced Cancer (NCT01050985) | Georgetown University | 2010-07-01 |
| A Phase 1 Dose Escalation Study of AMG 780 in Adult Subjects With Advanced Solid Tumors (NCT01137552) | Amgen | 2010-06-01 |
| Study of Oral Darinaparsin in Patients With Advanced Solid Tumors (NCT01139346) | Alaunos Therapeutics | 2010-06-01 |
| Study to Evaluate Panobinostat (DACi) Pharmacokinetics and Safety in Solid Tumors and Varying Renal Function (NCT00997399) | Novartis Pharmaceuticals | 2010-03-01 |
| Safety Study of Bevacizumab, Everolimus and LBH589 (BEL) for Advanced Solid Tumors (NCT01055795) | Herbert Hurwitz | 2010-03-01 |
| A Safety, Tolerability, And Pharmacokinetic Trial With CVX-241 In Patients With Advanced Solid Tumors (NCT01004822) | Pfizer | 2010-03-01 |
| A Molecular Pharmacodynamic Dose-titration Trial of Conjugated Linoleic Acid (CLA; Clarinol®) in Patients With Advanced Solid Tumors (NCT00951158) | Dartmouth-Hitchcock Medical Center | 2010-03-01 |
| ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Advanced Solid Tumors (NCT01110486) | AbbVie (prior sponsor, Abbott) | 2010-03-01 |
| Pharmacokinetics and Safety of Panobinostat in Patients With Advanced Solid Tumors and Various Degrees of Hepatic Function (NCT01007968) | Novartis Pharmaceuticals | 2010-03-01 |
| A Study Of Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic Regimens (NCT01009190) | pharmaand GmbH | 2010-02-01 |
| Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors (NCT01056029) | GenSpera, Inc. | 2010-01-01 |
| A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid Tumors (NCT01063816) | AbbVie (prior sponsor, Abbott) | 2010-01-01 |
| Sorafenib Plus S-1 in Advanced Solid Tumors (NCT01128998) | National Health Research Institutes, Taiwan | 2009-11-01 |
| Lenalidomide and Paclitaxel in Advanced Solid Tumors (NCT01155505) | Southern Europe New Drug Organization | 2009-11-01 |
| Effect of Food and Antacid on BIIB021 With Advanced Solid Tumors (NCT01017198) | Biogen | 2009-11-01 |
| Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma (NCT00996957) | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | 2009-10-01 |
| Study of TAK-901 in Adults With Advanced Solid Tumors or Lymphoma (NCT00935844) | Millennium Pharmaceuticals, Inc. | 2009-10-01 |
| Study of MLN8237 in Participants With Advanced Solid Tumors (NCT00962091) | Millennium Pharmaceuticals, Inc. | 2009-09-25 |
| A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (MK-2206-015) (NCT00963547) | Merck Sharp & Dohme LLC | 2009-09-15 |
| Dose Escalation and PK Study of M2ES in Subjects With Advanced Solid Tumors (NCT01226030) | Protgen Ltd | 2009-09-01 |
| This Is The First Study Using Escalating Doses Of PF-03758309, An Oral Compound, In Patients With Advanced Solid Tumors (NCT00932126) | Pfizer | 2009-09-01 |
| Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors (NCT00827177) | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 2009-09-01 |
| A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors (NCT00858377) | Amgen | 2009-08-10 |
| A Study of ARRY-438162 (MEK162) in Patients With Advanced Cancer (NCT00959127) | Array Biopharma, now a wholly owned subsidiary of Pfizer | 2009-08-01 |
| Pharmacodynamics (PD) and Pharmacokinetics (PK) Study of EP-100 in Advanced Solid Tumors (NCT00949559) | Esperance Pharmaceuticals Inc | 2009-07-01 |
| A Phase I Study to Assess the Safety, Pharmacokinetics, and Potential Effects of Amrubicin on the QT/QTc Interval in Cancer Patients With Advanced Solid Tumors. (NCT00915083) | Celgene | 2009-06-01 |
| Study With Atu027 in Patients With Advanced Solid Cancer (NCT00938574) | Silence Therapeutics GmbH | 2009-06-01 |
| A Study to Determine the Metabolism and Elimination of 14C-E7080 in Patients With Advanced Solid Tumors or Lymphomas, Who Are Unsuitable For, or Have Failed, Existing Therapies. (NCT02578316) | Eisai Inc. | 2009-06-01 |
| Single Dose Study of [14C]-Labelled AMG 706 in Patients With Advanced Solid Tumors (NCT01386866) | Amgen | 2009-05-01 |
| Study of NMS-1116354 in Solid Tumors (NCT01016327) | Nerviano Medical Sciences | 2009-04-01 |
| Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Solid Tumors (NCT00793897) | Bristol-Myers Squibb | 2009-04-01 |
| A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors (NCT00999401) | Cyclacel Pharmaceuticals, Inc. | 2009-04-01 |
| Dose Escalation Study of ARQ 197 in Combination With Gemcitabine in Adult Patients With Advanced Solid Tumors (NCT00874042) | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 2009-03-01 |
| Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors (NCT00877474) | PharmaMar | 2009-03-01 |
| Phase I Study of TAK-701 in Adult Patients With Advanced Nonhematological Malignancies (NCT00831896) | Millennium Pharmaceuticals, Inc. | 2009-03-01 |
| Sorafenib in Combination With RAD001 in Advanced Solid Tumors Selected on Molecular Targets (NCT01226056) | Southern Europe New Drug Organization | 2009-03-01 |
| A Study to Determine the Metabolism and Elimination of Carbon-14 Labeled Eribulin Acetate (14C-Eribulin) in Patients With Advanced Solid Tumors (NCT00908908) | Eisai Inc. | 2009-03-01 |
| A Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, in Patients With Advanced Solid Tumors (NCT00842335) | Jubilant Innovation Ltd. | 2009-02-01 |
| Dose-escalation Study of Oral CX-4945 (NCT00891280) | Cylene Pharmaceuticals | 2009-02-01 |
| Pharmacokinetic Study To Evaluate Effect of Food and Diurnal Variation on ABT-869 (NCT00733187) | AbbVie (prior sponsor, Abbott) | 2009-02-01 |
| Ascending Multiple-Dose Study of BMS-817378 in Subjects With Advanced Cancers (NCT00792558) | Bristol-Myers Squibb | 2009-01-01 |
| A Single Center Study to Characterize the Absorption, Distribution, Metabolism and Excretion (ADME) of ASA404 After a Single Infusion in Patients With Solid Tumors (NCT01299701) | Novartis Pharmaceuticals | 2008-12-01 |
| A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors (NCT00813384) | Amgen | 2008-12-01 |
| Phase I AZD2281/Cisplatin in Advanced Solid Tumour Patients (NCT00782574) | AstraZeneca | 2008-11-12 |
| Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced Cancer (NCT00688415) | Celgene | 2008-11-07 |
| Dose Escalation Study of AUY922 in Advanced Solid Malignancies in Japan (NCT01132625) | Novartis Pharmaceuticals | 2008-11-01 |
| Safety and Efficacy of LCL161 in Patients With Solid Tumors (NCT01098838) | Novartis Pharmaceuticals | 2008-11-01 |
| A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®) (NCT00739453) | Astellas Pharma Inc | 2008-10-23 |
| Phase I Dose Escalating Study of TKI258 (NCT01471548) | Novartis Pharmaceuticals | 2008-09-01 |
| Study Of CP-751,871 In Combination With Sunitinib In Patients With Advanced Solid Tumors (NCT00729833) | Pfizer | 2008-09-01 |
| Phase I and Pharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients With Solid Tumors or Lymphoma (NCT00947739) | New Mexico Cancer Research Alliance | 2008-09-01 |
| Phase I Study of Intravenous Lipotecan® (TLC388 HCl for Injection) in Patients With Advanced Solid Tumors (NCT00747474) | Taiwan Liposome Company | 2008-09-01 |
| Phase 1 Study of the Effect of Ketoconazole on the PK of Multiple Doses of Cediranib in Patients With Solid Tumours (NCT00750425) | AstraZeneca | 2008-08-01 |
| Phase I Study of U3P1287/01, Including Patients With Advanced Solid Tumors (NCT00730470) | U3 Pharma GmbH | 2008-08-01 |
| A Safety Study in Participants With Advanced Solid Tumors (NCT01284335) | Eli Lilly and Company | 2008-07-01 |
| Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment (NCT00734305) | Merrimack Pharmaceuticals | 2008-07-01 |
| Administration of BIIB028 to Subjects With Solid Tumors (NCT00725933) | Biogen | 2008-06-01 |
| Phase 1b Study of Indibulin in Combination With Capecitabine in Advanced Solid Tumors (NCT00726687) | Alaunos Therapeutics | 2008-06-01 |
| Phase I Trial of Oral PX-866 (NCT00726583) | Cascadian Therapeutics Inc. | 2008-06-01 |
| LBH589 Oral in Combination With Carboplatin and Paclitaxel in Advanced Solid Tumors (NCT01159418) | Southern Europe New Drug Organization | 2008-06-01 |
| A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors (NCT00708006) | Human Genome Sciences Inc. | 2008-05-01 |
| Phase 1 Trial of Oral Ixabepilone (NCT00632424) | R-Pharm | 2008-05-01 |
| EMD 640 744 in Montanide ISA 51 VG Administered in Subjects With Advanced Solid Tumors (NCT01012102) | Merck KGaA, Darmstadt, Germany | 2008-04-01 |